bioblast


Also found in: Dictionary.

bioblast

(1) An obsolete term for a microscopic particle, the modern translation of which may include mitochondrion. 
(2) An obsolete term for a hypothetical unit of living matter with an autonomous capacity for growth and division, as well as stimulation of cell functions.
Mentioned in ?
References in periodicals archive ?
Stevens will be a participant of BioBlast's Executive Committee and will manage, in specific, the corporate policy, M&A, and business development of marketed and upgrade stage in- and out-licensing.
Colin Foster, President and Chief Executive Officer of BioBlast said, "I'm thrilled to have Terri join our executive team given her impressive global experience in corporate strategy, M&A, and business development."
"I am excited to work closely with Colin and the executive team to help BioBlast leverage its corporate development opportunities and in so doing, achieve a higher strategic trajectory.
EcoSure BioBlast fibers have been under development for two years and just completed 365 days of testing with Eden Research Lab, a third-party vendor in New Mexico.
"EcoSure BioBlast fiber incorporates Poole Company's 100% post-consumer polymer and engineered additives to accelerate microbiological activity," says Joe McFadyen, technical director at Poole Company.
Now in its third year of development, the BioBlast project represents the collaboration of an interdisciplinary team of experts:
We focus here on the innovative qualities of BioBLAST as a learning environment and the indispensable role the teacher-leader group has had in the project.
Supporting a constructivist approach to learning, BioBLAST consists of a suite of "authentic" tasks.
* The report provides brief overview of Bioblast Pharma Ltd.
* The report reviews current pipeline of Bioblast Pharma Ltd.'s human therapeutic division and enlists all their major and minor projects
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Tuesday the receipt of a notice of allowance from the US Patent and Trademark Office (USPTO) for the composition and method of Cabaletta for the treatment of oculopharyngeal muscular dystrophy (OPMD).
Dalia Megiddo, MD, chief executive officer of BioBlast, said, 'This patent covers the significant innovations we have made in the delivery of therapeutic proteins into mitochondria.